News

The Department Chair of Neurosciences at Cleveland Clinic was a leading part of the group of researchers that recently identified the new subtype of multiple sclerosis.

Lutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.

Darin Okuda, MD, spoke about the new investigative therapies for MS, as well as the expanding role of disease-modifying therapies.

What is known about chronic inflammatory demyelinating polyradiculoneuropathy, a neurological disorder marked by by progressive weakness and impaired sensory function in the extremeties?

Investigators have identified a new subtype of MS in postmortem tissue, characterized by a lack of cerebral white matter demyelination.

The designation is backed by positive interim data from ASPIRO, which has demonstrated significant improvements in neuromuscular and respiratory function at week 24.

The approval is backed by the effectiveness established in 2, 12-week studies in patients with Dravet syndrome, and open-label long-term studies.

Patients treated with fludrocortisone normalized their serum sodium levels in only 4 days—significantly quicker than saline alone, which took 15 days.

Patients administered A-tDCS during outpatient speech therapy were shown to have a relative increase of 70% in correct-naming for A-tDCS compared to sham.

Hendrix spoke to the challenges he and colleagues come across, as well as his hope for the promising future.

A nationwide, case-controlled study found the use of benzodiazepines and related z-drugs increased the risk of patients developing Alzheimer disease.

The director of the Partners Pediatric Multiple Sclerosis Center at Massachusetts General Hospital spoke about the current landscape of MS treatment.

Robbins discusses the exciting future of true designer drugs in the works for migraine prevention as well as the challenges that remain in the space.

Seasickness can be difficult to manage once symptoms begin. However, there are some physiological characteristics to help patients manage symptoms.

Selkoe spoke to a number of topics in the Alzheimer space, including the challenges in the field and his excitement for the future.

For those at-risk for Parkinson disease, reducing systemic inflammation could decrease the incidence of the movement disorder.

Lutz Frölich, MD, PhD, discussed the imperativeness of collaboration between stakeholders—clinicians, pharmaceutical companies, researchers—in developing therapies for Alzheimer disease.

The results indicated that 38% of patients responded to the device whereas 11% of patients responded when using the sham device.

The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.

This is the first study to utilize artificial intelligence for detecting a wide range of acute neurologic events, demonstrating a direct clinical application.

The nonselective ß-blocker proved efficacious in comparison with placebo in a pilot trial.

The investigational drug is in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping.

Livingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.

Darin Okuda, MD, provides insight into the nuances that come with the treatment of MS with disease-modifying therapies.

The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health talked about the biggest challenges facing medicine in treating and understanding Alzheimer disease.

Could GlaxoSmithKline and 23andMe use genetic data to create landscape-altering therapies for hard-to-treat conditions?

DREAMS-START demonstrates that a manual-based psychological treatment for sleep disorders in dementia is feasible and acceptable.

Can better collaboration between industry and clinicians solve the challenges that plague the Alzheimer community?